Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

MLA

van der Schoot, Lara S., et al. “Regaining Adequate Treatment Responses in Patients with Psoriasis Who Discontinued Dose Reduction of Adalimumab, Etanercept or Ustekinumab.” The British Journal of Dermatology, vol. 187, no. 6, Dec. 2022, pp. 1028–30. EBSCOhost, https://doi.org/10.1111/bjd.21797.

APA

van der Schoot, L. S., Atalay, S., Otero, M. E., Kievit, W., van den Reek, J. M. P. A., & de Jong, E. M. G. J. (2022). Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. The British Journal of Dermatology, 187(6), 1028–1030. https://doi.org/10.1111/bjd.21797

Chicago

van der Schoot, Lara S, Selma Atalay, Marisol E Otero, Wietske Kievit, Juul M P A van den Reek, and Elke M G J de Jong. 2022. “Regaining Adequate Treatment Responses in Patients with Psoriasis Who Discontinued Dose Reduction of Adalimumab, Etanercept or Ustekinumab.” The British Journal of Dermatology 187 (6): 1028–30. doi:10.1111/bjd.21797.